---
title: Predict who benefits after infusion
nct_id: NCT06080399
status: RECRUITING
sponsor: University Hospital, Toulouse
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06080399"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06080399"
last_fetched: "2026-05-10T14:05:23.116Z"
source: "Parkinson's Pathways (curated)"
---
# Predict who benefits after infusion

**Goal (in five words):** Predict who benefits after infusion

**Official Title:** Could Psycho-bio-social Context and Personality be a Predictive Factor of Quality of Life Amelioration After Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease Patients? - PERSO-PERF Study

**Trial ID:** [NCT06080399](https://clinicaltrials.gov/study/NCT06080399)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** University Hospital, Toulouse
- **Target Enrollment:** 70 participants
- **Start Date:** 2024-02-15
- **Completion Date:** 2026-04-01
- **Conditions:** Parkinson Disease
- **Interventions:** Continuous subcutaneous apomorphine infusion (CSAI)
- **Intervention Types:** OTHER

## Summary For Families

The goal is to find out whether a person’s personality, psychological and social situation, plus biological factors, predict who will have a real improvement in quality of life after starting continuous subcutaneous apomorphine infusion. Apomorphine is a fast-acting dopamine agonist given continuously under the skin to provide steadier stimulation of dopamine receptors, often smoothing levodopa on/off swings and reducing off time; the study simply follows patients starting CSAI as part of usual care while measuring mood, personality, social supports and medical factors. They are enrolling people about 40 to 75 years old with Parkinson’s by UKPDSBB criteria who have motor fluctuations or disabling dyskinesia and are awaiting CSAI, excluding those with atypical parkinsonism, prior deep brain stimulation, certain psychiatric disorders, MoCA under 24, major medical problems, or legal guardianship.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Parkinson's disease patients as defined by the United Kingdom Parkinson's disease Brain Bank (UKPDSBB) criteria and aged from 40 to 75 years old (included)
* Patients with motor fluctuations and/or invalidating dyskinesia and awaiting CSAI establishment in the context of their usual care for PD
* Patients affiliated to a social security system

Exclusion Criteria:

* Patients presenting an atypical parkinsonian syndrome Patients having a Deep Brain Stimulation
* Patients with a psychiatric disease such as bipolar disorder or delusions linked to a dopaminergic psychosis
* Patients presenting a cognitive deficit attested by a score to the Montreal Cognitive Assessment inferior to 24, solely during the inclusion (baseline - V0)
* Patient with a serious pathology (e.g. cancer) or a health condition which could interfere with the assessment of their quality of life, at the discretion of the investigator upon inclusion
* Patients under guardianship, curatorship or safeguard of justice
* Patients under exclusion period from another study
```

## Locations (10)

- Chu de Lyon, Bron, France _(45.7386, 4.9130)_
  - STEPHANE THOBOIS — (CONTACT) — stephane.thobois@chu-lyon.fr
- Hopital Gabriel Montpied, Clermont-Ferrand, France _(45.7797, 3.0868)_
  - ANA MARQUES — (CONTACT) — ar_marques@chu-clermontferrand.fr
- Chu de Grenoble, Grenoble, France _(45.1787, 5.7148)_
  - ELENA MORO — (CONTACT) — emoro@chu-grenoble.fr
- Chu Limoges, Limoges, France _(45.8336, 1.2476)_
  - JEAN-LUC HOUETO — (CONTACT) — Jean-Luc.HOUETO@chu-limoges.fr
- Chu de Nancy, Nancy, France _(48.6844, 6.1850)_
  - SOLENE FRISMAND — (CONTACT) — s.frismand@chru-nancy.fr
- Chu de Nice, Nice, France _(43.7031, 7.2661)_
  - CAROLINE GIORDANA — (CONTACT) — GIORDANA.C@chu-nice.fr
- Chu de Poitiers, Poitiers, France _(46.5826, 0.3435)_
  - ISABELLE BENATRU — (CONTACT) — Isabelle.BENATRU@chu-poitiers.fr
- Chu de Rennes, Rennes, France _(48.1111, -1.6743)_
  - SOPHIE DRAPIER — (CONTACT) — Sophie.Drapier@chu-rennes.fr
- Chu de Rouen, Rouen, France _(49.4431, 1.0993)_
  - DAVID MALTETE — (CONTACT) — David.Maltete@chu-rouen.fr
- Chu de Toulouse, Toulouse, France _(43.6043, 1.4437)_
  - CHRISTINE BREFEL COURBON — (CONTACT) — christine.brefel-courbon@univ-tlse3.fr

## Central Contacts

- CHRISTINE BREFEL COURBON — (CONTACT) — (0)5 61 77 25 35 — christine.brefel-courbon@univ-tlse3.fr
- ESTELLE HARROCH — (CONTACT) — harroch.e@chu-toulouse.fr

---

*Canonical: https://parkinsonspathways.com/trial/NCT06080399*  
*HTML version: https://parkinsonspathways.com/trial/NCT06080399*  
*Source data: https://clinicaltrials.gov/study/NCT06080399*